- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mereo BioPharma Group PLC ADR (MREO)
Mereo BioPharma Group PLC ADR stock price live, this page displays NASDAQ MREO stock exchange data. View the MREO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mereo BioPharma Group PLC ADR real time stock price chart below.
What Is the Mereo BioPharma Group PLC ADR Stock Price Today?
The Mereo BioPharma Group PLC ADR stock price today is 2.180.
What Is the Stock Symbol for Mereo BioPharma Group PLC ADR?
The stock symbol for Mereo BioPharma Group PLC ADR is "MREO."
What Stock Exchange Does Mereo BioPharma Group PLC ADR Trade On?
Mereo BioPharma Group PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Mereo BioPharma Group PLC ADR a Good Stock to Buy?
Determining whether Mereo BioPharma Group PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MREO quote. (ISIN: US5894921072)
What Is the Mereo BioPharma Group PLC ADR Stock Price Today?
The Mereo BioPharma Group PLC ADR stock price today is 2.180.
What Is the Stock Symbol for Mereo BioPharma Group PLC ADR?
The stock symbol for Mereo BioPharma Group PLC ADR is "MREO."
What Stock Exchange Does Mereo BioPharma Group PLC ADR Trade On?
Mereo BioPharma Group PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Mereo BioPharma Group PLC ADR a Good Stock to Buy?
Determining whether Mereo BioPharma Group PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MREO quote. (ISIN: US5894921072)
2.180
-0.130(-5.63%)
Closed·
Pre Market
2.260+0.080(+3.67%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.150
2.300
52 wk Range
1.575
5.020
MREO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MREO is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1502.300
52 wk Range
1.5755.020
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MREO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.597
Upside
+248.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Mereo BioPharma Group PLC ADR Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Mereo BioPharma Group PLC ADR SWOT Analysis
Pipeline Promise | Explore Mereo BioPharma's late-stage assets: setrusumab for osteogenesis imperfecta and alvelestat for AATD, poised to transform rare disease treatment |
Market Potential | Delve into setrusumab's commercial prospects, with EU revenue potentially exceeding $500M by mid-2030s and a lean sales force requirement |
Financial Health | Learn about Mereo's strong cash position, supporting operations into 2027, and its attractive valuation relative to perceived opportunity |
Analyst Outlook | Discover Wall Street's optimism with price targets ranging from $6.41 to $10.68, significantly above the current $2.53 share price |
Compare MREO to Peers and Sector
Metrics to compare | MREO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMREOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.3x | −2.9x | −0.5x | |
PEG Ratio | 0.10 | −0.01 | 0.00 | |
Price/Book | 5.8x | 1.8x | 2.6x | |
Price / LTM Sales | - | 8.1x | 2.9x | |
Upside (Analyst Target) | 219.6% | 231.0% | 45.8% | |
Fair Value Upside | Unlock | 26.3% | 8.6% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.597
(+248.47% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.02 / 0.01
Revenue / Forecast
-- / 26.88M
People Also Watch
FAQ
What Is the Mereo BioPharma ADR (MREO) Stock Price Today?
The Mereo BioPharma ADR stock price today is 2.18
What Stock Exchange Does Mereo BioPharma ADR Trade On?
Mereo BioPharma ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Mereo BioPharma ADR?
The stock symbol for Mereo BioPharma ADR is "MREO."
What Is the Mereo BioPharma ADR Market Cap?
As of today, Mereo BioPharma ADR market cap is 346.62M.
What Is Mereo BioPharma ADR's Earnings Per Share (TTM)?
The Mereo BioPharma ADR EPS (TTM) is -0.31.
When Is the Next Mereo BioPharma ADR Earnings Date?
Mereo BioPharma ADR will release its next earnings report on 06 Oct 2025.
From a Technical Analysis Perspective, Is MREO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.